Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные рекомендации по лечению остеоартроза
Современные рекомендации по лечению остеоартроза
Чичасова Н.В. Современные рекомендации по лечению остеоартроза. Consilium Medicum. 2016; 18 (2): 124–133. DOI: 10.26442/2075-1753_2016.2.124-133
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье представлены современные национальные и международные рекомендации по ведению больных остеоартрозом. Учитывая высокую мультиморбидность больных остеоартрозом, представлены данные по предупреждению осложнений лекарственной терапии и усугубления течения сопутствующих заболеваний. Показаны анальгетические и противовоспалительные возможности симптоммодифицирующих медленнодействующих препаратов (symptomatic slow-acting drug for osteoarthritis – SYSADOA) в лечении остеоартроза. Представлены данные отечественных и зарубежных авторов по эффективности комбинированных препаратов из группы SYSADOA.
Ключевые слова: остеоартроз, алгоритм лечения, мультиморбидность, симптоммодифицирующие медленнодействующие препараты.
Key words: osteoarthritis, treatment algorithm, multimorbid, symptom-modifying slow release formulations.
Ключевые слова: остеоартроз, алгоритм лечения, мультиморбидность, симптоммодифицирующие медленнодействующие препараты.
________________________________________________
Key words: osteoarthritis, treatment algorithm, multimorbid, symptom-modifying slow release formulations.
Полный текст
Список литературы
1. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377: 2115–26
2. Pereira D, Peleteiro D, Araujo J et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartilage 2011; 19: 1279–85.
3. Галушко Е.А., Большакова Т.В., Виноградова И.Б. и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практ. ревматология. 2009; 1: 11–7. / Galushko E.A., Bol'shakova T.V., Vinogradova I.B. i dr. Struktura revmaticheskikh zabolevanii sredi vzroslogo naseleniia Rossii po dannym epidemiologicheskogo issledovaniia (predvaritel'nye rezul'taty). Nauchno-prakt. revmatologiia. 2009; 1: 11–7. [in Russian]
4. World Health Statistics 2012. Geneva: World Health Organization.
5. Global, regional, and national incidence, prevalence, and year lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013; a systematic analysis for the Global burden of disease Study. 2013 Global Burden of Disease Study. 2013 Collaborators//www.thelancet.com. Published online June 8, 2015.
6. Hootman JM, Helmick CG, Golightly YM. Trends in prevalence of knee pain among US adults, National Health Interview Survey, 2002–2010. Arthr Rheum 2015, 67 (S10): Abstract Suppl. 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 3269.
7. Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ. 2008; 16 (7): 33–7. / Vertkin A.L., Alekseeva L.I., Naumov A.V. i dr. Osteoartroz v praktike vracha-terapevta. RMZh. 2008; 16 (7): 33–7. [in Russian]
8. Van Dijk GV, Veenhof C, Schelleviset S et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008; 9: 95.
9. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363–88.
10. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Ed. Arthritis and Allied Conditions. A Textbook of Rheumatology 13th edn. Baltimore: Williams & Wilkins, 1969; 1984; 1997.
11. Haseb A, Haggi TM. Immunopathogenesis of osteoarthritis NIH. Clin Immunol 2013; 146: 185–96.
12. Osteoarthritis. Clinical and Experimental aspects. Ed. J.-E.Reginster, J.-P.Pelletier, Y.Henrotin. Springer, 1999.
13. Benito MJ, Veale DJ, FitzGerald O et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263–7.
14. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthr Res Ther 2008: 10 (Suppl. 2): 3.
15. Murphy G, Lee MH. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 2005; 64: iv44–iv47.
16. Andersen TL, del Carmen Ovejero M, Kirkegaard T et al. A scrutinu of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by over cells. Bone 2004; 35: 1107–19.
17. Алексеева Л.И., Насонов Е.Л. Национальные рекомендации по ведению больных ОА. Официальный сайт ФГБУН «Научно-исследовательский институт ревматологии им. В.А.Насоновой» rheumatology.ru / Alekseeva L.I., Nasonov E.L. Natsional'nye rekomendatsii po vedeniiu bol'nykh OA. Ofitsial'nyi sait FGBUN “Nauchno-issledovatel'skii institut revmatologii im. V.A.Nasonovoi” rheumatology.ru [in Russian]
18. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике. М.: ИМА-ПРЕСС, 2015. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike. M.: IMA-PRESS, 2015. [in Russian]
19. Helin-Salmivaara A et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scand J Gastroenterology 2007; 428: 923–32.
20. Conroy RM, Pyorala K, Fitzgerald AP et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
21. Jordan KM, Arden NK, Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
22. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendation for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74 [review].
23. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Ostearthr Cartilage 2007; 15: 981–1000.
24. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based expert consensus guidelines. Ostearthr Cartilage 2008; 16: 137–62.
25. Zhang W, Nuki G, Moskowitz RW et al. OARSI recommendation for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartilage 2010; 18: 476–99.
26. Bannuri RR, Dasi UR, McAlindon TE. Reassessing the role of acetaminophen in osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartilage 2010; 18 (Suppl. 2): S250.
27. Herrero-Beaumont G, Ivrora JA, Del Carmen Trabado M et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthr Rheum 2007; 56: 555–67.
28. Muller-Fabender H, Bach GL, Haase W et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2 (3): 61–9.
29. Алексеева Л.И., Беневоленская Л.И., Насонов Е.Л. и др. Структум (хондроитин-сульфат) – новое средство для лечения остеоартроза. Терапевт. арх. 1999; 5: 51–3. / Alekseeva L.I., Benevolenskaia L.I., Nasonov E.L. i dr. Struktum (khondroitin-sul'fat) – novoe sredstvo dlia lecheniia osteoartroza. Terapevt. arkh. 1999; 5: 51–3. [in Russian]
30. Yaron I, Shirasi R, Judovich R, Yaron M. Chondroitin sulfate inhibits prostaglandin E2 production in synovial cell cultures and reverses IL-1 inhibition of cartilage synthesis. Ann Rheum Dis 2000; 59 (Suppl. 1): 265.
31. Mazieres B, Combe B, Phan Van V et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheum 2001; 28: 173–81.
32. Reginster JY, Deroisy R, Rovati IC et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 367: 251–6.
33. Pavelka K, Gatterova J, Olejarova M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomised, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23
34. Wandel S, Juni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Br Med J 2010; 341: c4675.
35. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–75.
36. Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
37. Richy F, Bruyere O, Ethgen O. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–22.
38. Pelletier JP, Raunauld JP, Beaulieu A et al. In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients. Arthr Rheum 2015, 67 (S10): Abstract Supplement 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 950.
39. Lippielo L, Woodword J, Karpman D et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
40. Лила А.М., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618–22. / Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
41. Lippiello L. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000; 381: 229–40.
42. Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med 2007; 4 (2): 219–24.
43. Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795–808.
44. Алексеева Л.И., Беневоленская Л.И., Зайцева Е.М. Эффективность препарата Терафлекс у больных с остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). РМЖ. 2005; 13 (8): 525–7. / Alekseeva L.I., Benevolenskaia L.I., Zaitseva E.M. Effektivnost' preparata Terafleks u bol'nykh s osteoartrozom kolennykh i tazobedrennykh sustavov (otkrytoe randomizirovannoe issledovanie). RMZh. 2005; 13 (8): 525–7. [in Russian]
45. Лила А.М., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и остеохондроза позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618–22. / Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i osteokhondroza pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
46. Маличенко С.Б., Колесова И.Р. Изучение клинической эффективности и переносимости препарата Терафлекс (глюкозамин гидрохлорид – 500 мг и натрий хондроитин сульфата – 400 мг) при суставном синдроме у женщин в физиологической и хирургической менопаузе (отчет). М., 2005. / Malichenko S.B., Kolesova I.R. Izuchenie klinicheskoi effektivnosti i perenosimosti preparata Terafleks (gliukozamin gidrokhlorid – 500 mg i natrii khondroitin sul'fata – 400 mg) pri sustavnom sindrome u zhenshchin v fiziologicheskoi i khirurgicheskoi menopauze (otchet). M., 2005. [in Russian]
47. Алексеева Л.И. Результаты открытого сравнительного рандомизированного исследования эффективности и безопасности 2-х схем лечения препаратом Терафлекс у пациентов с остеоартрозом коленного сустава. Клиническое исследование. РМЖ. 2008; 16 (5): 316–9. / Alekseeva L.I. Rezul'taty otkrytogo sravnitel'nogo randomizirovannogo issledovaniia effektivnosti i bezopasnosti 2-kh skhem lecheniia preparatom Terafleks u patsientov s osteoartrozom kolennogo sustava. Klinicheskoe issledovanie. RMZh. 2008; 16 (5): 316–9. [in Russian]
48. Hochberg MC, Martel-Pelletier J, Monfort J et.al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75: 37–44.
49. Castellsague J et al. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf 2012; 35 (12): 1127–46.
50. Fournier JP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study Eur J Clin Pharmacol 2012; 68: 1533–40. DOI 10.1007/s00228-012-1283-9
51. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098. doi:10.1371/journal.pmed.1001098
52. Tallarida RJ, Cowan A, Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther 2003; 307: 699–704.
53. Алексеева Л.И. Открытое рандомизированное сравнительное исследование эффективности и безопасности препарата Терафлекс Адванс по сравнению с препаратами Терафлекс и ибупрофен у пациентов с остеоартрозом коленных суставов. Научный отчет. 2008. / Alekseeva L.I. Otkrytoe randomizirovannoe sravnitel'noe issledovanie effektivnosti i bezopasnosti preparata Terafleks Advans po sravneniiu s preparatami Terafleks i ibuprofen u patsientov s osteoartrozom kolennykh sustavov. Nauchnyi otchet. 2008. [in Russian]
54. Поворознюк В.В. Эффективность препарата Терафлекс Адванс в лечении болевого синдрома при остеоартрозе коленных суставов. Здоров'я Украины. 2007; 1–3. / Povorozniuk V.V. Effektivnost' preparata Terafleks Advans v lechenii bolevogo sindroma pri osteoartroze kolennykh sustavov. Zdorov'ia Ukrainy. 2007; 1–3. [in Russian]
55. Орлова С.П., Любарский Е.А., Термалаян Н.В., Хозин А.А. Отчет о применении препарата Терафлекс в лечении вертеброгенных болей. 1 неврологическое отделение МЛПУЗ «Городская больница №4». Р.-н/Д. / Orlova S.P., Liubarskii E.A., Termalaian N.V., Khozin A.A. Otchet o primenenii preparata Terafleks v lechenii vertebrogennykh bolei. 1 nevrologicheskoe otdelenie MLPUZ “Gorodskaia bol'nitsa №4”. R.-n/D. [in Russian]
56. Fairbank J, Mbaot JC, Davies JB, O`Brien JP. The Oswestry Low Back Pain Disability Questionnaire. Physiotherapy 1980; 66: 271–4.
57. Fransen M, Agaliotis M, Nairin L et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014; 73: 1–8. doi:10.1136/annrheumdis-2013-203954
58. Martin-Pelletier J, Roubille C, Abram F et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547–56.
2. Pereira D, Peleteiro D, Araujo J et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartilage 2011; 19: 1279–85.
3. Galushko E.A., Bol'shakova T.V., Vinogradova I.B. i dr. Struktura revmaticheskikh zabolevanii sredi vzroslogo naseleniia Rossii po dannym epidemiologicheskogo issledovaniia (predvaritel'nye rezul'taty). Nauchno-prakt. revmatologiia. 2009; 1: 11–7. [in Russian]
4. World Health Statistics 2012. Geneva: World Health Organization.
5. Global, regional, and national incidence, prevalence, and year lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013; a systematic analysis for the Global burden of disease Study. 2013 Global Burden of Disease Study. 2013 Collaborators//www.thelancet.com. Published online June 8, 2015.
6. Hootman JM, Helmick CG, Golightly YM. Trends in prevalence of knee pain among US adults, National Health Interview Survey, 2002–2010. Arthr Rheum 2015, 67 (S10): Abstract Suppl. 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 3269.
7. Vertkin A.L., Alekseeva L.I., Naumov A.V. i dr. Osteoartroz v praktike vracha-terapevta. RMZh. 2008; 16 (7): 33–7. [in Russian]
8. Van Dijk GV, Veenhof C, Schelleviset S et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008; 9: 95.
9. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363–88.
10. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Ed. Arthritis and Allied Conditions. A Textbook of Rheumatology 13th edn. Baltimore: Williams & Wilkins, 1969; 1984; 1997.
11. Haseb A, Haggi TM. Immunopathogenesis of osteoarthritis NIH. Clin Immunol 2013; 146: 185–96.
12. Osteoarthritis. Clinical and Experimental aspects. Ed. J.-E.Reginster, J.-P.Pelletier, Y.Henrotin. Springer, 1999.
13. Benito MJ, Veale DJ, FitzGerald O et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263–7.
14. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthr Res Ther 2008: 10 (Suppl. 2): 3.
15. Murphy G, Lee MH. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 2005; 64: iv44–iv47.
16. Andersen TL, del Carmen Ovejero M, Kirkegaard T et al. A scrutinu of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by over cells. Bone 2004; 35: 1107–19.
17. Alekseeva L.I., Nasonov E.L. Natsional'nye rekomendatsii po vedeniiu bol'nykh OA. Ofitsial'nyi sait FGBUN “Nauchno-issledovatel'skii institut revmatologii im. V.A.Nasonovoi” rheumatology.ru [in Russian]
18. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike. M.: IMA-PRESS, 2015. [in Russian]
19. Helin-Salmivaara A et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scand J Gastroenterology 2007; 428: 923–32.
20. Conroy RM, Pyorala K, Fitzgerald AP et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
21. Jordan KM, Arden NK, Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
22. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendation for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74 [review].
23. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Ostearthr Cartilage 2007; 15: 981–1000.
24. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based expert consensus guidelines. Ostearthr Cartilage 2008; 16: 137–62.
25. Zhang W, Nuki G, Moskowitz RW et al. OARSI recommendation for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartilage 2010; 18: 476–99.
26. Bannuri RR, Dasi UR, McAlindon TE. Reassessing the role of acetaminophen in osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartilage 2010; 18 (Suppl. 2): S250.
27. Herrero-Beaumont G, Ivrora JA, Del Carmen Trabado M et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthr Rheum 2007; 56: 555–67.
28. Muller-Fabender H, Bach GL, Haase W et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2 (3): 61–9.
29. Alekseeva L.I., Benevolenskaia L.I., Nasonov E.L. i dr. Struktum (khondroitin-sul'fat) – novoe sredstvo dlia lecheniia osteoartroza. Terapevt. arkh. 1999; 5: 51–3. [in Russian]
30. Yaron I, Shirasi R, Judovich R, Yaron M. Chondroitin sulfate inhibits prostaglandin E2 production in synovial cell cultures and reverses IL-1 inhibition of cartilage synthesis. Ann Rheum Dis 2000; 59 (Suppl. 1): 265.
31. Mazieres B, Combe B, Phan Van V et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheum 2001; 28: 173–81.
32. Reginster JY, Deroisy R, Rovati IC et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 367: 251–6.
33. Pavelka K, Gatterova J, Olejarova M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomised, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23
34. Wandel S, Juni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Br Med J 2010; 341: c4675.
35. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–75.
36. Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
37. Richy F, Bruyere O, Ethgen O. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–22.
38. Pelletier JP, Raunauld JP, Beaulieu A et al. In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients. Arthr Rheum 2015, 67 (S10): Abstract Supplement 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 950.
39. Lippielo L, Woodword J, Karpman D et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
40. Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
41. Lippiello L. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000; 381: 229–40.
42. Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med 2007; 4 (2): 219–24.
43. Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795–808.
44. Alekseeva L.I., Benevolenskaia L.I., Zaitseva E.M. Effektivnost' preparata Terafleks u bol'nykh s osteoartrozom kolennykh i tazobedrennykh sustavov (otkrytoe randomizirovannoe issledovanie). RMZh. 2005; 13 (8): 525–7. [in Russian]
45. Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i osteokhondroza pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
46. Malichenko S.B., Kolesova I.R. Izuchenie klinicheskoi effektivnosti i perenosimosti preparata Terafleks (gliukozamin gidrokhlorid – 500 mg i natrii khondroitin sul'fata – 400 mg) pri sustavnom sindrome u zhenshchin v fiziologicheskoi i khirurgicheskoi menopauze (otchet). M., 2005. [in Russian]
47. Alekseeva L.I. Rezul'taty otkrytogo sravnitel'nogo randomizirovannogo issledovaniia effektivnosti i bezopasnosti 2-kh skhem lecheniia preparatom Terafleks u patsientov s osteoartrozom kolennogo sustava. Klinicheskoe issledovanie. RMZh. 2008; 16 (5): 316–9. [in Russian]
48. Hochberg MC, Martel-Pelletier J, Monfort J et.al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75: 37–44.
49. Castellsague J et al. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf 2012; 35 (12): 1127–46.
50. Fournier JP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study Eur J Clin Pharmacol 2012; 68: 1533–40. DOI 10.1007/s00228-012-1283-9
51. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098. doi:10.1371/journal.pmed.1001098
52. Tallarida RJ, Cowan A, Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther 2003; 307: 699–704.
53. Alekseeva L.I. Otkrytoe randomizirovannoe sravnitel'noe issledovanie effektivnosti i bezopasnosti preparata Terafleks Advans po sravneniiu s preparatami Terafleks i ibuprofen u patsientov s osteoartrozom kolennykh sustavov. Nauchnyi otchet. 2008. [in Russian]
54. Povorozniuk V.V. Effektivnost' preparata Terafleks Advans v lechenii bolevogo sindroma pri osteoartroze kolennykh sustavov. Zdorov'ia Ukrainy. 2007; 1–3. [in Russian]
55. Orlova S.P., Liubarskii E.A., Termalaian N.V., Khozin A.A. Otchet o primenenii preparata Terafleks v lechenii vertebrogennykh bolei. 1 nevrologicheskoe otdelenie MLPUZ “Gorodskaia bol'nitsa №4”. R.-n/D. [in Russian]
56. Fairbank J, Mbaot JC, Davies JB, O`Brien JP. The Oswestry Low Back Pain Disability Questionnaire. Physiotherapy 1980; 66: 271–4.
57. Fransen M, Agaliotis M, Nairin L et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014; 73: 1–8. doi:10.1136/annrheumdis-2013-203954
58. Martin-Pelletier J, Roubille C, Abram F et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547–56.
2. Pereira D, Peleteiro D, Araujo J et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartilage 2011; 19: 1279–85.
3. Галушко Е.А., Большакова Т.В., Виноградова И.Б. и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практ. ревматология. 2009; 1: 11–7. / Galushko E.A., Bol'shakova T.V., Vinogradova I.B. i dr. Struktura revmaticheskikh zabolevanii sredi vzroslogo naseleniia Rossii po dannym epidemiologicheskogo issledovaniia (predvaritel'nye rezul'taty). Nauchno-prakt. revmatologiia. 2009; 1: 11–7. [in Russian]
4. World Health Statistics 2012. Geneva: World Health Organization.
5. Global, regional, and national incidence, prevalence, and year lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013; a systematic analysis for the Global burden of disease Study. 2013 Global Burden of Disease Study. 2013 Collaborators//www.thelancet.com. Published online June 8, 2015.
6. Hootman JM, Helmick CG, Golightly YM. Trends in prevalence of knee pain among US adults, National Health Interview Survey, 2002–2010. Arthr Rheum 2015, 67 (S10): Abstract Suppl. 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 3269.
7. Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ. 2008; 16 (7): 33–7. / Vertkin A.L., Alekseeva L.I., Naumov A.V. i dr. Osteoartroz v praktike vracha-terapevta. RMZh. 2008; 16 (7): 33–7. [in Russian]
8. Van Dijk GV, Veenhof C, Schelleviset S et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008; 9: 95.
9. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363–88.
10. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Ed. Arthritis and Allied Conditions. A Textbook of Rheumatology 13th edn. Baltimore: Williams & Wilkins, 1969; 1984; 1997.
11. Haseb A, Haggi TM. Immunopathogenesis of osteoarthritis NIH. Clin Immunol 2013; 146: 185–96.
12. Osteoarthritis. Clinical and Experimental aspects. Ed. J.-E.Reginster, J.-P.Pelletier, Y.Henrotin. Springer, 1999.
13. Benito MJ, Veale DJ, FitzGerald O et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263–7.
14. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthr Res Ther 2008: 10 (Suppl. 2): 3.
15. Murphy G, Lee MH. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 2005; 64: iv44–iv47.
16. Andersen TL, del Carmen Ovejero M, Kirkegaard T et al. A scrutinu of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by over cells. Bone 2004; 35: 1107–19.
17. Алексеева Л.И., Насонов Е.Л. Национальные рекомендации по ведению больных ОА. Официальный сайт ФГБУН «Научно-исследовательский институт ревматологии им. В.А.Насоновой» rheumatology.ru / Alekseeva L.I., Nasonov E.L. Natsional'nye rekomendatsii po vedeniiu bol'nykh OA. Ofitsial'nyi sait FGBUN “Nauchno-issledovatel'skii institut revmatologii im. V.A.Nasonovoi” rheumatology.ru [in Russian]
18. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике. М.: ИМА-ПРЕСС, 2015. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike. M.: IMA-PRESS, 2015. [in Russian]
19. Helin-Salmivaara A et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scand J Gastroenterology 2007; 428: 923–32.
20. Conroy RM, Pyorala K, Fitzgerald AP et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
21. Jordan KM, Arden NK, Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
22. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendation for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74 [review].
23. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Ostearthr Cartilage 2007; 15: 981–1000.
24. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based expert consensus guidelines. Ostearthr Cartilage 2008; 16: 137–62.
25. Zhang W, Nuki G, Moskowitz RW et al. OARSI recommendation for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartilage 2010; 18: 476–99.
26. Bannuri RR, Dasi UR, McAlindon TE. Reassessing the role of acetaminophen in osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartilage 2010; 18 (Suppl. 2): S250.
27. Herrero-Beaumont G, Ivrora JA, Del Carmen Trabado M et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthr Rheum 2007; 56: 555–67.
28. Muller-Fabender H, Bach GL, Haase W et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2 (3): 61–9.
29. Алексеева Л.И., Беневоленская Л.И., Насонов Е.Л. и др. Структум (хондроитин-сульфат) – новое средство для лечения остеоартроза. Терапевт. арх. 1999; 5: 51–3. / Alekseeva L.I., Benevolenskaia L.I., Nasonov E.L. i dr. Struktum (khondroitin-sul'fat) – novoe sredstvo dlia lecheniia osteoartroza. Terapevt. arkh. 1999; 5: 51–3. [in Russian]
30. Yaron I, Shirasi R, Judovich R, Yaron M. Chondroitin sulfate inhibits prostaglandin E2 production in synovial cell cultures and reverses IL-1 inhibition of cartilage synthesis. Ann Rheum Dis 2000; 59 (Suppl. 1): 265.
31. Mazieres B, Combe B, Phan Van V et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheum 2001; 28: 173–81.
32. Reginster JY, Deroisy R, Rovati IC et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 367: 251–6.
33. Pavelka K, Gatterova J, Olejarova M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomised, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23
34. Wandel S, Juni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Br Med J 2010; 341: c4675.
35. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–75.
36. Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
37. Richy F, Bruyere O, Ethgen O. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–22.
38. Pelletier JP, Raunauld JP, Beaulieu A et al. In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients. Arthr Rheum 2015, 67 (S10): Abstract Supplement 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 950.
39. Lippielo L, Woodword J, Karpman D et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
40. Лила А.М., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618–22. / Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
41. Lippiello L. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000; 381: 229–40.
42. Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med 2007; 4 (2): 219–24.
43. Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795–808.
44. Алексеева Л.И., Беневоленская Л.И., Зайцева Е.М. Эффективность препарата Терафлекс у больных с остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). РМЖ. 2005; 13 (8): 525–7. / Alekseeva L.I., Benevolenskaia L.I., Zaitseva E.M. Effektivnost' preparata Terafleks u bol'nykh s osteoartrozom kolennykh i tazobedrennykh sustavov (otkrytoe randomizirovannoe issledovanie). RMZh. 2005; 13 (8): 525–7. [in Russian]
45. Лила А.М., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и остеохондроза позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618–22. / Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i osteokhondroza pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
46. Маличенко С.Б., Колесова И.Р. Изучение клинической эффективности и переносимости препарата Терафлекс (глюкозамин гидрохлорид – 500 мг и натрий хондроитин сульфата – 400 мг) при суставном синдроме у женщин в физиологической и хирургической менопаузе (отчет). М., 2005. / Malichenko S.B., Kolesova I.R. Izuchenie klinicheskoi effektivnosti i perenosimosti preparata Terafleks (gliukozamin gidrokhlorid – 500 mg i natrii khondroitin sul'fata – 400 mg) pri sustavnom sindrome u zhenshchin v fiziologicheskoi i khirurgicheskoi menopauze (otchet). M., 2005. [in Russian]
47. Алексеева Л.И. Результаты открытого сравнительного рандомизированного исследования эффективности и безопасности 2-х схем лечения препаратом Терафлекс у пациентов с остеоартрозом коленного сустава. Клиническое исследование. РМЖ. 2008; 16 (5): 316–9. / Alekseeva L.I. Rezul'taty otkrytogo sravnitel'nogo randomizirovannogo issledovaniia effektivnosti i bezopasnosti 2-kh skhem lecheniia preparatom Terafleks u patsientov s osteoartrozom kolennogo sustava. Klinicheskoe issledovanie. RMZh. 2008; 16 (5): 316–9. [in Russian]
48. Hochberg MC, Martel-Pelletier J, Monfort J et.al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75: 37–44.
49. Castellsague J et al. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf 2012; 35 (12): 1127–46.
50. Fournier JP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study Eur J Clin Pharmacol 2012; 68: 1533–40. DOI 10.1007/s00228-012-1283-9
51. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098. doi:10.1371/journal.pmed.1001098
52. Tallarida RJ, Cowan A, Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther 2003; 307: 699–704.
53. Алексеева Л.И. Открытое рандомизированное сравнительное исследование эффективности и безопасности препарата Терафлекс Адванс по сравнению с препаратами Терафлекс и ибупрофен у пациентов с остеоартрозом коленных суставов. Научный отчет. 2008. / Alekseeva L.I. Otkrytoe randomizirovannoe sravnitel'noe issledovanie effektivnosti i bezopasnosti preparata Terafleks Advans po sravneniiu s preparatami Terafleks i ibuprofen u patsientov s osteoartrozom kolennykh sustavov. Nauchnyi otchet. 2008. [in Russian]
54. Поворознюк В.В. Эффективность препарата Терафлекс Адванс в лечении болевого синдрома при остеоартрозе коленных суставов. Здоров'я Украины. 2007; 1–3. / Povorozniuk V.V. Effektivnost' preparata Terafleks Advans v lechenii bolevogo sindroma pri osteoartroze kolennykh sustavov. Zdorov'ia Ukrainy. 2007; 1–3. [in Russian]
55. Орлова С.П., Любарский Е.А., Термалаян Н.В., Хозин А.А. Отчет о применении препарата Терафлекс в лечении вертеброгенных болей. 1 неврологическое отделение МЛПУЗ «Городская больница №4». Р.-н/Д. / Orlova S.P., Liubarskii E.A., Termalaian N.V., Khozin A.A. Otchet o primenenii preparata Terafleks v lechenii vertebrogennykh bolei. 1 nevrologicheskoe otdelenie MLPUZ “Gorodskaia bol'nitsa №4”. R.-n/D. [in Russian]
56. Fairbank J, Mbaot JC, Davies JB, O`Brien JP. The Oswestry Low Back Pain Disability Questionnaire. Physiotherapy 1980; 66: 271–4.
57. Fransen M, Agaliotis M, Nairin L et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014; 73: 1–8. doi:10.1136/annrheumdis-2013-203954
58. Martin-Pelletier J, Roubille C, Abram F et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547–56.
________________________________________________
2. Pereira D, Peleteiro D, Araujo J et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartilage 2011; 19: 1279–85.
3. Galushko E.A., Bol'shakova T.V., Vinogradova I.B. i dr. Struktura revmaticheskikh zabolevanii sredi vzroslogo naseleniia Rossii po dannym epidemiologicheskogo issledovaniia (predvaritel'nye rezul'taty). Nauchno-prakt. revmatologiia. 2009; 1: 11–7. [in Russian]
4. World Health Statistics 2012. Geneva: World Health Organization.
5. Global, regional, and national incidence, prevalence, and year lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013; a systematic analysis for the Global burden of disease Study. 2013 Global Burden of Disease Study. 2013 Collaborators//www.thelancet.com. Published online June 8, 2015.
6. Hootman JM, Helmick CG, Golightly YM. Trends in prevalence of knee pain among US adults, National Health Interview Survey, 2002–2010. Arthr Rheum 2015, 67 (S10): Abstract Suppl. 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 3269.
7. Vertkin A.L., Alekseeva L.I., Naumov A.V. i dr. Osteoartroz v praktike vracha-terapevta. RMZh. 2008; 16 (7): 33–7. [in Russian]
8. Van Dijk GV, Veenhof C, Schelleviset S et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008; 9: 95.
9. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363–88.
10. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Ed. Arthritis and Allied Conditions. A Textbook of Rheumatology 13th edn. Baltimore: Williams & Wilkins, 1969; 1984; 1997.
11. Haseb A, Haggi TM. Immunopathogenesis of osteoarthritis NIH. Clin Immunol 2013; 146: 185–96.
12. Osteoarthritis. Clinical and Experimental aspects. Ed. J.-E.Reginster, J.-P.Pelletier, Y.Henrotin. Springer, 1999.
13. Benito MJ, Veale DJ, FitzGerald O et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263–7.
14. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthr Res Ther 2008: 10 (Suppl. 2): 3.
15. Murphy G, Lee MH. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 2005; 64: iv44–iv47.
16. Andersen TL, del Carmen Ovejero M, Kirkegaard T et al. A scrutinu of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by over cells. Bone 2004; 35: 1107–19.
17. Alekseeva L.I., Nasonov E.L. Natsional'nye rekomendatsii po vedeniiu bol'nykh OA. Ofitsial'nyi sait FGBUN “Nauchno-issledovatel'skii institut revmatologii im. V.A.Nasonovoi” rheumatology.ru [in Russian]
18. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike. M.: IMA-PRESS, 2015. [in Russian]
19. Helin-Salmivaara A et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scand J Gastroenterology 2007; 428: 923–32.
20. Conroy RM, Pyorala K, Fitzgerald AP et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
21. Jordan KM, Arden NK, Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
22. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendation for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74 [review].
23. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Ostearthr Cartilage 2007; 15: 981–1000.
24. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based expert consensus guidelines. Ostearthr Cartilage 2008; 16: 137–62.
25. Zhang W, Nuki G, Moskowitz RW et al. OARSI recommendation for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartilage 2010; 18: 476–99.
26. Bannuri RR, Dasi UR, McAlindon TE. Reassessing the role of acetaminophen in osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartilage 2010; 18 (Suppl. 2): S250.
27. Herrero-Beaumont G, Ivrora JA, Del Carmen Trabado M et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthr Rheum 2007; 56: 555–67.
28. Muller-Fabender H, Bach GL, Haase W et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2 (3): 61–9.
29. Alekseeva L.I., Benevolenskaia L.I., Nasonov E.L. i dr. Struktum (khondroitin-sul'fat) – novoe sredstvo dlia lecheniia osteoartroza. Terapevt. arkh. 1999; 5: 51–3. [in Russian]
30. Yaron I, Shirasi R, Judovich R, Yaron M. Chondroitin sulfate inhibits prostaglandin E2 production in synovial cell cultures and reverses IL-1 inhibition of cartilage synthesis. Ann Rheum Dis 2000; 59 (Suppl. 1): 265.
31. Mazieres B, Combe B, Phan Van V et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheum 2001; 28: 173–81.
32. Reginster JY, Deroisy R, Rovati IC et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 367: 251–6.
33. Pavelka K, Gatterova J, Olejarova M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomised, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23
34. Wandel S, Juni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Br Med J 2010; 341: c4675.
35. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–75.
36. Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
37. Richy F, Bruyere O, Ethgen O. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–22.
38. Pelletier JP, Raunauld JP, Beaulieu A et al. In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients. Arthr Rheum 2015, 67 (S10): Abstract Supplement 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 950.
39. Lippielo L, Woodword J, Karpman D et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
40. Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
41. Lippiello L. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000; 381: 229–40.
42. Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med 2007; 4 (2): 219–24.
43. Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795–808.
44. Alekseeva L.I., Benevolenskaia L.I., Zaitseva E.M. Effektivnost' preparata Terafleks u bol'nykh s osteoartrozom kolennykh i tazobedrennykh sustavov (otkrytoe randomizirovannoe issledovanie). RMZh. 2005; 13 (8): 525–7. [in Russian]
45. Lila A.M., Mazurov V.I., Shidlovskaia O.V., Shostak M.S. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i osteokhondroza pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
46. Malichenko S.B., Kolesova I.R. Izuchenie klinicheskoi effektivnosti i perenosimosti preparata Terafleks (gliukozamin gidrokhlorid – 500 mg i natrii khondroitin sul'fata – 400 mg) pri sustavnom sindrome u zhenshchin v fiziologicheskoi i khirurgicheskoi menopauze (otchet). M., 2005. [in Russian]
47. Alekseeva L.I. Rezul'taty otkrytogo sravnitel'nogo randomizirovannogo issledovaniia effektivnosti i bezopasnosti 2-kh skhem lecheniia preparatom Terafleks u patsientov s osteoartrozom kolennogo sustava. Klinicheskoe issledovanie. RMZh. 2008; 16 (5): 316–9. [in Russian]
48. Hochberg MC, Martel-Pelletier J, Monfort J et.al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75: 37–44.
49. Castellsague J et al. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf 2012; 35 (12): 1127–46.
50. Fournier JP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study Eur J Clin Pharmacol 2012; 68: 1533–40. DOI 10.1007/s00228-012-1283-9
51. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098. doi:10.1371/journal.pmed.1001098
52. Tallarida RJ, Cowan A, Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther 2003; 307: 699–704.
53. Alekseeva L.I. Otkrytoe randomizirovannoe sravnitel'noe issledovanie effektivnosti i bezopasnosti preparata Terafleks Advans po sravneniiu s preparatami Terafleks i ibuprofen u patsientov s osteoartrozom kolennykh sustavov. Nauchnyi otchet. 2008. [in Russian]
54. Povorozniuk V.V. Effektivnost' preparata Terafleks Advans v lechenii bolevogo sindroma pri osteoartroze kolennykh sustavov. Zdorov'ia Ukrainy. 2007; 1–3. [in Russian]
55. Orlova S.P., Liubarskii E.A., Termalaian N.V., Khozin A.A. Otchet o primenenii preparata Terafleks v lechenii vertebrogennykh bolei. 1 nevrologicheskoe otdelenie MLPUZ “Gorodskaia bol'nitsa №4”. R.-n/D. [in Russian]
56. Fairbank J, Mbaot JC, Davies JB, O`Brien JP. The Oswestry Low Back Pain Disability Questionnaire. Physiotherapy 1980; 66: 271–4.
57. Fransen M, Agaliotis M, Nairin L et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014; 73: 1–8. doi:10.1136/annrheumdis-2013-203954
58. Martin-Pelletier J, Roubille C, Abram F et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547–56.
Авторы
Н.В.Чичасова
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
kafedrarheum@yandex.ru
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
kafedrarheum@yandex.ru
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
kafedrarheum@yandex.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
kafedrarheum@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.